Adaptimmune Therapeutics plc

  • Home
  • Our Company
    • Overview arrow_forward
    • Partners arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
    • Scientific Advisory Board arrow_forward
    • Perspectives arrow_forward
  • Pipeline
    • Clinical Pipeline arrow_forward
    • Afami-cel arrow_forward
    • ADP-A2M4CD8 arrow_forward
    • Preclinical Pipeline arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Cancer Info arrow_forward
    • Videos arrow_forward
    • Engagement with Patient Organizations arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Preclinical Pipeline

Pipeline

Pipeline

  • Clinical Pipeline
  • Afami-cel
  • ADP-A2M4CD8
  • Preclinical Pipeline

Preclinical autologous and allogeneic pipeline

Our deep preclinical pipeline includes both autologous and allogeneic therapies.

Adding to our ongoing MAGE-A4 directed autologous program, we are also focusing on the development of a T-cell therapy directed to PRAME - another of the most validated T-cell targets in solid tumors.

We have built one of the leading allogeneic T-cell platforms using human induced pluripotent stem cell lines (hIPSCs). This platform is flexible, scalable, and produces functional T-cells that kill tumor cells in vitro. We will combine this platform with everything we have learned from decades of autologous T-cell therapy research and development into a pipeline for Adaptimmune and its partners for off-the-shelf cell or allogeneic T-cell therapies. We plan to file our first allogeneic IND in 2025.

Preclinical autologous and allogeneic pipeline

Publications

Review our findings and publications.

View Preclinical and Allogeneic Publications View All Publications

Latest News

We announced clinical responses across five solid tumor indications with an overall response rate of 36% and promising early durability from our next-generation SURPASS trial.

View Press Release
Adaptimmune Therapeutics plc
Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2023 Adaptimmune Therapeutics plc. All Rights Reserved.